At present, we do not have enough information to apply the same parameters, particularly those linked to molecular brain changes at pre‐clinical stages and pre‐clinical biomarkers, to fAD caused by mutations in APP, PSEN1, and PSEN2. The gene discussed is APP; the disease is familial Alzheimer disease.